Acute and Chronic Urticaria (Hives): Antihistamines, Triggers, and Emergency Care

Pathophysiology of Urticaria and Angioedema

Urticaria, commonly known as hives, is a vascular reaction of the skin characterized by the rapid onset of pruritic, erythematous, edematous plaques called wheals. These lesions are transient, typically resolving within 24 hours without leaving permanent marks. Pathophysiologically, urticaria is driven by the activation and degranulation of mast cells and basophils. Upon activation, these cells release preformed inflammatory mediators, primarily histamine, along with newly synthesized leukotrienes, prostaglandins, and cytokines. Histamine binds to H1 receptors on vascular endothelial cells, causing local vasodilation and increased capillary permeability, leading to dermal edema (the wheal) and sensory nerve stimulation (causing pruritus). When this swelling occurs in the deeper dermis, subcutaneous, or submucosal tissues, it is termed angioedema. Angioedema is often non-pruritic but can be painful and life-threatening if it involves the upper airway.

Differentiating Acute vs. Chronic Urticaria

Clinical management of urticaria requires a clear categorization based on duration, as the diagnostic workup and prognosis differ substantially:

• Acute Urticaria: Defined as hives that occur for less than 6 weeks. The vast majority of acute cases are self-limiting. Common triggers include viral upper respiratory infections, medications (such as nonsteroidal anti-inflammatory drugs [NSAIDs], beta-lactam antibiotics), food allergens (peanuts, shellfish), and insect stings. In many cases, the exact cause is never identified, and extensive laboratory testing is not indicated unless specific exposures are suspected.
• Chronic Urticaria: Defined as hives that recur at least twice weekly for 6 weeks or longer. Chronic urticaria is further divided into Chronic Spontaneous Urticaria (CSU), which occurs without an identifiable external trigger, and Chronic Inducible Urticaria (CIndU), which is triggered by specific physical stimuli such as cold, heat, pressure, vibration, solar exposure, or exercise (cholinergic urticaria). Up to 40% of CSU cases have an autoimmune etiology, characterized by IgG autoantibodies directed against the IgE receptor (FcεRI) or IgE itself.

Pharmacological Management Guidelines

Treatment guidelines from the Joint Task Force on Practice Parameters and international consensus documents recommend a structured, step-care approach to managing chronic urticaria:

1. First-Line Therapy: Daily administration of a standard-dose, second-generation (non-sedating) H1 antihistamine (e.g., fexofenadine, loratadine, desloratadine, or levocetirizine). First-generation H1 antihistamines (like diphenhydramine or hydroxyzine) are discouraged for routine daily use due to their central nervous system side effects, including sedation and cognitive impairment.
2. Second-Line Therapy: If symptoms persist after 1 to 2 weeks, the dose of the second-generation H1 antihistamine can be titrated up to four times the standard licensed dose.
3. Third-Line Therapy: For patients refractory to high-dose antihistamines, the addition of omalizumab—a monoclonal antibody that binds to circulating IgE, downregulating FcεRI receptors on mast cells—is highly effective.
4. Fourth-Line Therapy: Immunosuppressants such as cyclosporine may be considered for patients who do not respond to omalizumab. Short-term courses of oral corticosteroids may be used to control severe exacerbations, but they should never be used as long-term maintenance therapy due to systemic toxicities.

💡 💡 Recognizing Anaphylaxis and Emergency Care

Ensure that patients can distinguish between simple hives and anaphylaxis. Anaphylaxis is a systemic, life-threatening IgE-mediated reaction. Red flags include respiratory distress (wheezing, stridor, dyspnea), laryngeal edema, hypotension, dizziness, or gastrointestinal symptoms (vomiting, abdominal cramps). If these signs occur, intramuscular epinephrine (0.3 mg in adults) must be administered immediately, and emergency services contacted.

Physical Triggers and Diagnosis

For patients with inducible urticaria, identifying and avoiding specific physical triggers is vital. In physical urticarias, symptoms can be reproduced in a clinical setting to confirm the diagnosis. For example, symptomatic dermatographism (whealing from friction) is confirmed by stroking the skin with a blunt object, which produces a linear wheal. Cold urticaria is diagnosed using the “ice cube test,” where an ice cube is placed on the forearm for 5 minutes, and a wheal forms as the skin rewarms. Cholinergic urticaria, triggered by elevated core body temperature (e.g., from exercise, hot baths, or emotional stress), presents as tiny, highly pruritic punctate wheals. Patients experiencing localized, non-wheal contact reactions should be evaluated for contact dermatitis, which is pathologically distinct from mast-cell-driven urticaria and does not respond to standard antihistamine up-dosing.

💡 Frequently Asked Questions (FAQ)

Q1: What is the difference between urticaria and angioedema?
A1: Urticaria (hives) involves swelling in the superficial dermis, presenting as intensely itchy, red, raised wheals that fade within 24 hours. Angioedema involves swelling in the deeper subcutaneous or submucosal tissues, often presenting as asymmetrical, painful swelling of the face, lips, tongue, or extremities, and can last for several days.

Q2: Why do chronic hives often occur without an identifiable trigger?
A2: Up to 80-90% of chronic urticaria cases are spontaneous, meaning they occur without an external trigger. This is because chronic spontaneous urticaria is frequently driven by internal autoimmune mechanisms, where autoantibodies stimulate mast cells directly, rather than an external allergy.

Q3: Can stress cause hives?
A3: Psychological stress is a well-known exacerbating factor. Stress triggers the release of neuropeptides, corticotropin-releasing hormone, and catecholamines, which can lower the threshold for mast cell degranulation, causing flares in patients who are already prone to urticaria.

📚 References & Sources

1. Zuberbier, T., et al. (2022). The EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy, 77(3), 734-766.
2. Bernstein, J. A., et al. (2014). The diagnosis and management of acute and chronic urticaria: 2014 update. Journal of Allergy and Clinical Immunology, 134(5), 1014-1025.